

News Releases

All Years

Search

Go

[Advanced Search](#)

JAN 4, 2022

Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data

DEC 1, 2021

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

NOV 9, 2021

Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

NOV 3, 2021

Inhibrx Announces Presentations at SITC 2021

NOV 1, 2021

Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences

Show 5  per page

[«](#) [1](#) [...](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [»](#)



